In short
BI 690517, also known as Vicadrostat, is an investigational drug currently being studied in various clinical trials. These trials aim to evaluate its safety, efficacy, and potential benefits in treating chronic kidney disease, particularly in patients with diabetic nephropathy. The studies explore how the drug is absorbed and processed by the body, its effects on kidney function, and its potential to slow the progression of kidney disease when used alone or in combination with other medications.
At a glance
- Drug Name
- BI 690517 (Vicadrostat)
- Primary Focus
- Treatment of chronic kidney disease, particularly diabetic nephropathy
- Trial Types
- Phase I, II, and III studies
- Study Populations
- Healthy volunteers, patients with chronic kidney disease, diabetic nephropathy patients
- Key Outcomes Measured
- Safety, tolerability, pharmacokinetics, pharmacodynamics, kidney function markers (e.g., UACR, eGFR)
- Administration
- Oral tablets, various dosing regimens
- Combination Therapies
- Studied with empagliflozin, ACEi, ARBs
- Special Populations
- Studies in Chinese and Japanese participants, patients with liver impairment
- Potential Benefits
- May slow kidney disease progression, reduce risk of heart failure and cardiovascular events
What is BI 690517?
BI 690517, also known as Vicadrostat, is a new drug being developed by pharmaceutical researchers. It is currently undergoing clinical trials to evaluate its effectiveness and safety in treating various conditions, primarily related to kidney and heart diseases. The drug is taken orally, usually in the form of tablets.
What Conditions Does BI 690517 Treat?
Based on the ongoing clinical trials, BI 690517 is being studied for its potential to treat:
- Chronic Kidney Disease (CKD): This is a condition where the kidneys are damaged and cannot filter blood as well as they should. BI 690517 is being tested to see if it can slow down the progression of CKD and reduce related complications.
- Heart Failure: This is a condition where the heart cannot pump blood effectively to meet the body's needs. BI 690517 is being studied to determine if it can help improve symptoms and outcomes in patients with heart failure.
How Does BI 690517 Work?
BI 690517 is classified as an aldosterone synthase inhibitor. To understand how it works:
- Aldosterone is a hormone that helps regulate blood pressure and the balance of salt and water in the body.
- Aldosterone synthase is an enzyme that produces aldosterone.
- By inhibiting (blocking) aldosterone synthase, BI 690517 aims to reduce the production of aldosterone in the body.
Excessive aldosterone can contribute to high blood pressure, fluid retention, and damage to the heart and kidneys. By reducing aldosterone levels, BI 690517 may help protect these organs and improve overall health in patients with kidney and heart diseases.
Clinical Trials and Research
BI 690517 is currently being studied in several clinical trials to evaluate its effectiveness, safety, and how it's processed by the body (pharmacokinetics). Some key aspects of these trials include:
- Dose-finding studies: Researchers are testing different doses of BI 690517 to determine the most effective and safe dose for patients.
- Effects on kidney function: Studies are measuring how BI 690517 affects markers of kidney health, such as the urine albumin-to-creatinine ratio (UACR), which indicates the amount of protein in the urine.
- Heart failure outcomes: Researchers are investigating whether BI 690517 can reduce hospitalizations for heart failure and improve survival in patients with heart problems.
- Long-term effects: Some trials are designed to last several years to assess the long-term benefits and safety of BI 690517.
Combination Therapy with Empagliflozin
Many of the clinical trials are studying BI 690517 in combination with another drug called empagliflozin. Empagliflozin is a medication already approved for treating type 2 diabetes and heart failure. The combination of these two drugs may provide additional benefits for patients with kidney and heart diseases. Researchers are investigating whether this combination can:
- Slow down the progression of chronic kidney disease more effectively than either drug alone.
- Reduce the risk of hospitalization and death in patients with heart failure.
- Improve overall kidney and heart health outcomes.
Safety and Side Effects
As BI 690517 is still in the research phase, its full safety profile and potential side effects are not yet fully known. The ongoing clinical trials are carefully monitoring participants for any adverse events (unwanted side effects). Some studies are specifically designed to assess how well the drug is tolerated by different groups of people, including:
- Healthy volunteers
- Patients with liver problems
- People of different ethnicities, such as Chinese and Japanese participants
These safety studies help researchers understand how the drug affects different populations and identify any potential risks or side effects.
Future Prospects
While BI 690517 shows promise in early research, it's important to note that it is still an experimental drug. The results of the ongoing clinical trials will determine whether it becomes approved for use in patients. If successful, BI 690517 could potentially offer a new treatment option for people with chronic kidney disease and heart failure, especially those who may not respond well to existing therapies.
As research continues, more information will become available about the effectiveness, safety, and potential uses of BI 690517. Patients interested in this drug should discuss with their healthcare providers about the latest developments and whether participating in a clinical trial might be appropriate for their individual situation.